Lumos Pharma - Stock Price History | LUMO

Historical daily share price chart and data for Lumos Pharma since 2021 adjusted for splits. The latest closing stock price for Lumos Pharma as of September 27, 2021 is 9.90.
  • The all-time high Lumos Pharma stock closing price was 511.88 on April 13, 2015.
  • The Lumos Pharma 52-week high stock price is 36.72, which is 270.9% above the current share price.
  • The Lumos Pharma 52-week low stock price is 7.23, which is 27% below the current share price.
  • The average Lumos Pharma stock price for the last 52 weeks is 13.66.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Lumos Pharma Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 14.5329 20.3420 35.9100 7.1200 35.7100 56.81%
2019 14.7341 14.9415 28.1728 10.5311 22.7723 66.45%
2018 40.9553 76.2376 90.5491 12.2412 13.6814 -81.26%
2017 106.3770 94.9595 216.9217 54.6355 72.9973 -21.11%
2016 133.9532 312.6013 312.6013 87.3987 92.5293 -71.75%
2015 394.3110 392.8893 511.8812 287.5788 327.5428 -8.45%
2014 256.2867 192.4392 453.6454 163.1863 357.7858 80.60%
2013 147.8887 107.2007 211.5212 101.4401 198.1098 76.08%
2012 107.0295 64.0864 159.2259 58.3258 112.5113 77.56%
2011 62.6595 63.7264 64.6265 57.3357 63.3663 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.083B $0.000B
Lumos Pharma Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's product pipeline consists of LUM-201 which is in clinical stage. Lumos Pharma Inc., formerly known as NewLink Genetics Corporation, is based in AUSTIN, Texas.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29